Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Astellas Pharma Inc
Exelixis
Mayo Clinic
Neonc Technologies, Inc.
Bristol-Myers Squibb
Genmab
Jazz Pharmaceuticals
Myeloid Therapeutics
IDEAYA Biosciences
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Hoffmann-La Roche
Innate Pharma
Mayo Clinic
Tanabe Pharma America, Inc.
Pfizer
EMD Serono
Mayo Clinic
LG Chem
Incyte Corporation
Pfizer
Tempest Therapeutics
Nurix Therapeutics, Inc.
Pfizer
Exelixis
Incyte Corporation
Jonsson Comprehensive Cancer Center
MacroGenics
Xencor, Inc.
National Institutes of Health Clinical Center (CC)
NuCana plc
University of Virginia
Incyte Corporation
NextPoint Therapeutics, Inc.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Monopar Therapeutics
Monopar Therapeutics
Klus Pharma Inc.
Aprea Therapeutics
Bristol-Myers Squibb
Checkpoint Therapeutics, Inc.
RAPT Therapeutics, Inc.
Cybrexa Therapeutics
Carisma Therapeutics Inc
Zumutor Biologics Inc.
Abbisko Therapeutics Co, Ltd
Molecular Templates, Inc.
Inhibrx Biosciences, Inc
Salubris Biotherapeutics Inc